Clinical Trials in Málaga, Malaga
25 recruiting
Showing 1–20 of 25 trials
Recruiting
Phase 2Phase 3
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Advanced Melanoma
Eikon Therapeutics740 enrolled107 locationsNCT06697301
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled207 locationsNCT06422143
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled218 locationsNCT06170788
Recruiting
Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC868 enrolled229 locationsNCT06077760
Recruiting
Phase 2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Neoplasm Malignant
Merck Sharp & Dohme LLC150 enrolled50 locationsNCT07209111
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled216 locationsNCT06345729
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC556 enrolled194 locationsNCT06074588
Recruiting
Phase 2
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled9 locationsNCT07284420
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled10 locationsNCT07294170
Recruiting
Phase 1Phase 2
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Non-small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament251 enrolled24 locationsNCT06043817
Recruiting
Not Applicable
NIMA-Colon Cancer Study
Colon Cancer
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud120 enrolled1 locationNCT07534852
Recruiting
Phase 2
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Adenocarcinoma, Pancreatic Ductal
Genentech, Inc.260 enrolled89 locationsNCT05968326
Recruiting
Phase 3
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
Hepatitis CHepatitis C, ChronicHepatitis C Virus Infection+1 more
Atea Pharmaceuticals, Inc.880 enrolled106 locationsNCT07037277
Recruiting
Phase 2
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Not Applicable
Mentalizing and Epistemic Trust in Patients With Anxiety and Depression.
DepressionAnxiety Disorders
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud100 enrolled1 locationNCT06833567
Recruiting
Phase 2
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
Type 2 Diabetes Mellitus
Hoffmann-La Roche240 enrolled51 locationsNCT07112872
Recruiting
Phase 1Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled55 locationsNCT06772623
Recruiting
Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
AbbVie520 enrolled264 locationsNCT05445778
Recruiting
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Psoriatic Arthritis
AbbVie1,200 enrolled132 locationsNCT06764693